How Can Low-Dose Ketamine, a 'Lifesaving' Drug for Major Depression, Alleviate Symptoms Within Hours? Nov. 18, 2024 — Neuroscientists have identified the binding site of low-dose ketamine ...
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...
Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...
After six weeks, both the treatment group and the placebo group experienced an average 12.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS). The drug also fell short in i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback